Kevin Noonan
This person does not yet have a bio.
Articles by Kevin Noonan
| 4 min read
Decision provides a consistent standard based on structure even though resulting scope may prove insufficient for justifying costs of commercialization
| 5 min read
Trying to overcome misinterpretations of the Supreme Court's decisions on patent eligibility by district courts and the Federal Circuit
| 5 min read
An ounce of prevention was certainly worth the pound of its eventual cure when it comes to assigning inventions
| 4 min read
The arguments over "first to invent" and ownership of CRISPR tech continue
| 4 min read
GlaxoSmithKline LLC v. Teva Pharmaceuticals (Fed. Cir. 2020) addresses what quantum of culpable conduct is required
| 5 min read
The same evidence that supports non-obviousness for patentability can also restrict the scope of what has been described
| 5 min read
Once again this year, the report highlights compulsory licensing as a particular concern with regard to pharmaceuticals and medical devices
| 4 min read
According to Kevin Noonan, writing about a recent court ruling, the answer is a resounding..."Maybe"
| 4 min read
Patent Docs' Kevin Noonan talks about the potential peril of using a layperson to provide expert testimony
| 4 min read
The Federal Circuit continuse to expand the scope of patent-ineligible invention in its recent iNo Therapeutics LLC v. Praxair Distribution Inc. decision, relying on Justice Breyer's exhortation, in his Mayo Collaborative Serv. Inc. v. Prometheus Laboratories opinion
| 3 min read
Kevin Noonan discusses a case in which the University of Texas sued Boston Scientific for patent infringement related to implantable drug-releasing biodegradable fibers
| 3 min read
Kevin Noonan discusses recent developments around researchers vying for ownership of aspects of the gene-editing technology directed to eukaryotic cells
